Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Leica Biosystems has signed an agreement to supply HealthTrust, a group purchasing organization and provider of total cost management solutions for health care facilities, with its broad range of histology instrumentation, laboratory consumables, and sample-tracking systems.
Bio SB, a molecular pathology company based in Santa Barbara, Calif., has announced that it will partner with Cancer Diagnostics Inc. to distribute the Bio SB line of IHC antibodies, chromogens, and ancillaries in the U.S. market.
Biosearch Technologies, a supplier of oligonucleotide components to the rapidly growing molecular diagnostics industry, announced that it has acquired worldwide rights to TurboFISH technology, a method for rapid single molecule RNA FISH. With the TurboFISH license, Biosearch maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers, The State University of New Jersey.
TriLink BioTechnologies, a provider of custom nucleic acid-based products, announced the launch of MitoPrimers, dilute-and-go primers for mitochondrial DNA PCR amplification and sequencing in forensic identification. The high sensitivity of mtDNA PCR amplification and sequencing allows forensic scientists to obtain information from evidence associated with homicides or other criminal investigations, body identifications, and cold cases, as well as small pieces of evidence containing little biological material.
Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.
Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.
Denville Scientific’s new Ultra EZpette high-precision digital pipettors provide accurate and precise liquid dispensing in an ergonomic design.
Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint’s New Targets discovery platform by deploying its X-Man isogenic cell lines.
Beckman Coulter Life Sciences has received 510(k) clearance from the FDA and an import medical device registration certificate from the China Food and Drug Administration for the in vitro diagnostic use of the Navios flow cytometry system.
Audit MicroControls has added Control LQ Spinal Fluid to its line of daily quality control products. This bi-level reference control consisting of human serum-based solutions simulates patient spinal fluid samples for monitoring the precision of laboratory testing procedures for chloride, glucose, IgA, IgG, IgM, lactate, LDH, microalbumin, microprotein, and sodium.
